Company: IXHL
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001213900-25-013783
Chunk: 34

Company: Incannex Healthcare Inc.
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 1
Chunk 34
---
  
     40% 
     57  
     90  
     (33) 
     (37)%
  
    Interest expense 
     (171) 
     -  
     (171) 
     (100)% 
     (171) 
     -  
     (171) 
     (100)%
  
    Change in fair value of convertible rights 
     (179) 
     -  
     (179) 
     (100)% 
     (179) 
     -  
     (179) 
     (100)%
  
    Change in fair value of warrant liabilities 
     (103) 
     -  
     (103) 
     (100)% 
     (103) 
     -  
     (103) 
     (100)%
  
    Other expenses 
     (1,095) 
     -  
     (1,095) 
     (100)% 
     (1,095) 
     -  
     (1,095) 
     (100)%
  
    Total other income / (expenses), net 
     (890) 
     2,742  
     (3,632) 
     (132)% 
     (55) 
     6,908  
     (6,963) 
     (101)%
  
    Currency translation adjustment, net of tax 
     (414) 
     927  
     (1,341) 
     (145)% 
     (75) 
     418  
     (493) 
     (118)%
  
    Comprehensive loss 
    $(6,308) 
    $(4,314) 
    $(1,994) 
     (46)% 
    $(11,388) 
    $(5,550) 
    $(5,838) 
     105%

18

Revenue from Customers

We have generated revenue from Clarion Clinics for patient services
for the three and six months ended December 31, 2024. However, we do not expect to generate material revenues unless and until our drug
candidates are approved.

Operating Expenses 

Research and development 

Research and development expenses consist primarily
of external and internal costs incurred in performing clinical and preclinical development